Matthew Angel
Chief Executive Officer bei Factor Bioscience, Inc.
Vermögen: 116 760 $ am 31.03.2024
Profil
Matthew Angel was the founder of Novellus LLC, which was founded in 2014, where he held the title of Chief Science Officer from 2014 to 2021.
He is also the founder of Exacis Biotherapeutics, Inc., which was founded in 2020, where he currently holds the title of Director & Chief Scientific Officer.
Additionally, Dr. Angel is the founder of Factor Bioscience, Inc., which was founded in 2011, where he currently holds the title of Chairman & Chief Executive Officer.
In his former jobs, Dr. Angel worked at Eterna Therapeutics, Inc. as President & Chief Executive Officer in 2023 and as President, Chief Executive Officer & Director from 2022 to 2023.
Dr. Angel obtained a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ETERNA THERAPEUTICS INC.
0,90% | 26.04.2023 | 48 650 ( 0,90% ) | 116 760 $ | 31.03.2024 |
Aktive Positionen von Matthew Angel
| Unternehmen | Position | Beginn |
|---|---|---|
Factor Bioscience, Inc.
 Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.01.2011 |
Exacis Biotherapeutics, Inc.
 Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Founder | 01.01.2020 |
Ehemalige bekannte Positionen von Matthew Angel
| Unternehmen | Position | Ende |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Chief Executive Officer | 31.12.2023 |
| ETERNA THERAPEUTICS INC. | Chief Executive Officer | 04.08.2023 |
Novellus LLC
 Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Founder | 01.07.2021 |
Ausbildung von Matthew Angel
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ETERNA THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Health Technology |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
